Day One Biopharmaceuticals’ (DAWN) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN) in a report issued on Thursday morning,Benzinga reports. The firm currently has a $36.00 price objective on the stock.

DAWN has been the topic of several other research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. The Goldman Sachs Group dropped their target price on Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating on the stock in a report on Tuesday, March 25th. JPMorgan Chase & Co. decreased their price target on Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating for the company in a report on Wednesday, March 5th. Bank of America lowered their price target on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Finally, Wedbush reaffirmed an “outperform” rating and set a $32.00 price objective on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $32.29.

Day One Biopharmaceuticals Stock Down 6.4 %

Shares of NASDAQ:DAWN opened at $7.22 on Thursday. Day One Biopharmaceuticals has a twelve month low of $7.06 and a twelve month high of $18.07. The stock’s 50 day moving average is $10.13 and its 200-day moving average is $12.39. The firm has a market capitalization of $731.78 million, a price-to-earnings ratio of -7.01 and a beta of -1.24.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.34). The business had revenue of $29.21 million for the quarter, compared to analyst estimates of $27.11 million. Equities research analysts anticipate that Day One Biopharmaceuticals will post -0.72 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 4,646 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $55,566.16. Following the sale, the general counsel now owns 39,602 shares of the company’s stock, valued at approximately $473,639.92. The trade was a 10.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Jeremy Bender sold 12,048 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $144,094.08. Following the completion of the transaction, the chief executive officer now owns 128,015 shares in the company, valued at approximately $1,531,059.40. The trade was a 8.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 21,064 shares of company stock valued at $251,925. Insiders own 8.40% of the company’s stock.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. FMR LLC lifted its position in shares of Day One Biopharmaceuticals by 73.9% during the 4th quarter. FMR LLC now owns 12,887,467 shares of the company’s stock valued at $163,284,000 after buying an additional 5,475,087 shares during the last quarter. Alyeska Investment Group L.P. purchased a new stake in Day One Biopharmaceuticals during the fourth quarter valued at about $31,829,000. Boxer Capital Management LLC purchased a new stake in Day One Biopharmaceuticals during the fourth quarter valued at about $15,077,000. Marshall Wace LLP bought a new position in Day One Biopharmaceuticals during the fourth quarter worth about $13,909,000. Finally, Estuary Capital Management LP increased its stake in shares of Day One Biopharmaceuticals by 35.5% in the fourth quarter. Estuary Capital Management LP now owns 3,716,777 shares of the company’s stock worth $47,092,000 after purchasing an additional 972,997 shares in the last quarter. 87.95% of the stock is owned by institutional investors.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.